UPDATE: Evelo Biosciences Inc. (EVLO) Announces Proposed $40M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Evelo Biosciences Inc. (EVLO) Prices 12M Share Common Offering at $3.75/Sh
June 25, 2020 5:46 AM EDTEvelo Biosciences, Inc. (NASDAQ: EVLO) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions. Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 1,800,000 shares of its common stock. The... More
Pre-Open Stock Movers 06/22: (EVOK) (IDEX) (SPCE) Higher; (NBRV) (AAL) (DAL) Lower (more...)
June 22, 2020 9:31 AM EDTToday's Pre-Open Stock Movers
Evoke Pharma (NASDAQ: EVOK) 88% HIGHER; FDA approval of GIMOTI nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. In addition, H.C. Wainwright upgraded shares from Neutral to Buy with a price target of $10.00.
Ideanomics (NASDAQ: IDEX) 27% HIGHER; announced that its subsidiary Mobile Energy Global (MEG) has secured an order from the city of Neijiang in... More
Evelo Biosciences Inc. (EVLO) Reports EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial
June 22, 2020 6:03 AM EDTEvelo Biosciences, Inc. (NASDAQ: EVLO) announced today that EDP1815 will be included in the TACTIC-E clinical trial. The trial will evaluate the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized patients at early stages of the disease. The trials lead investigator is Dr. Joseph Cheriyan, Consultant Clinical Pharmacologist at Addenbrookes Hospital in Cambridge, and is sponsored by Cambridge University Hospitals NHS Foundation Trust.
Dr. Cheriyan said, "This is a critical time in the fight against COVID-19, and I am... More
